JPH05255126A - Bitter taste-reducing composition - Google Patents
Bitter taste-reducing compositionInfo
- Publication number
- JPH05255126A JPH05255126A JP4081419A JP8141992A JPH05255126A JP H05255126 A JPH05255126 A JP H05255126A JP 4081419 A JP4081419 A JP 4081419A JP 8141992 A JP8141992 A JP 8141992A JP H05255126 A JPH05255126 A JP H05255126A
- Authority
- JP
- Japan
- Prior art keywords
- medicine
- bitter taste
- oil
- bitterness
- ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は、精油または精油成分を
配合して苦味を低減することを特徴とする苦味低減組成
物に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a bitterness-reducing composition characterized by blending an essential oil or an essential oil component to reduce bitterness.
【０００２】[0002]
【従来の技術】従来、医薬品または食品において苦味を
低減するには苦味を有する成分をカプセルに入れたり、
錠剤とした後にフィルムコートや糖衣することにより、
口中で舌と接触しない形態とする方法やレシチンを添加
する方法（特開昭 62-265234号公報）などが用いられて
きた。また、液状の医薬品または食品は服用や摂取が比
較的容易で、しかも成分の消化管吸収が速く他の形態よ
りも速効性であるため幅広い目的で用いられ、苦味を有
する成分を配合した水溶液では、強い甘味をもたせるい
わゆるシロップ剤とする方法、クエン酸及びクエン酸ア
ルカリ金属塩を添加する方法（特開昭 60-246325号公
報）、例えばコーヒーエッセンスなどのビター感を持つ
香料を添加する方法などによって苦味を低減する工夫が
なされてきた。2. Description of the Related Art Conventionally, in order to reduce bitterness in pharmaceuticals or foods, ingredients having bitterness are put in capsules,
After making a tablet, by film coating or sugar coating,
Methods such as a method of not contacting the tongue in the mouth and a method of adding lecithin (JP-A-62-265234) have been used. In addition, liquid pharmaceuticals or foods are relatively easy to take and ingest, and they are used for a wide range of purposes because they are rapidly absorbed by the gastrointestinal tract and more rapidly acting than other forms. , A method of forming a so-called syrup having a strong sweetness, a method of adding citric acid and an alkali metal salt of citric acid (JP-A-60-246325), a method of adding a flavor having a bitter feeling such as coffee essence, etc. Has been devised to reduce bitterness.
【０００３】[0003]
【発明が解決しようとする課題】しかしながら、苦味を
有する成分を含有する医薬品または食品に対する上記記
載の方法は、多数の製造工程を必要とするなど苦味の低
減に関して満足できるものではなく、特に固形及び液状
の両方の形態に応用できる方法はなかった。However, the above-described method for a drug or food containing a component having a bitter taste is not satisfactory in terms of bitterness reduction, for example, it requires a large number of manufacturing steps, and particularly solid and There was no method applicable to both liquid forms.
【０００４】[0004]
【課題を解決するための手段】本発明者らは前述の課題
を解決するために鋭意検討を重ねた結果、苦味を有する
成分に精油または精油成分を配合することによって苦味
を著しく低減できることを見い出し本発明を完成した。Means for Solving the Problems As a result of intensive studies for solving the above-mentioned problems, the present inventors have found that the bitterness can be remarkably reduced by adding an essential oil or an essential oil component to a component having a bitterness. The present invention has been completed.
【０００５】本発明において苦味を有する成分とは、例
えばコデイン、ジヒドロコデイン、グアヤコールスルホ
ン酸、グアイフェネシン、メチルエフェドリン、エフェ
ドリンなどの鎮咳薬、ウルソデソキシコール酸、ケノデ
オキシコール酸などの利胆薬、ビスベンチアミン、フル
スルチアミンなどのビタミン類、カフェインなどの中枢
興奮薬、オウレン、コウボク、ダイオウなどの生薬抽出
物、茶、ガラナなどのカフェインを含有する植物の抽出
物、ポリフェノール類を含有する植物の抽出物、イチョ
ウなどのフラボン誘導体を含有する植物の抽出物などが
挙げられる。In the present invention, the bitter components include, for example, antitussives such as codeine, dihydrocodeine, guaiacol sulfonic acid, guaifenesin, methylephedrine and ephedrine, choleretic agents such as ursodesoxycholic acid and chenodeoxycholic acid, and bisbentamine. , Vitamins such as fursultiamine, central stimulants such as caffeine, crude drug extracts such as Coptis chinensis, Koubo, Rhubarb, extracts of plants containing caffeine such as tea and guarana, and plants containing polyphenols. Examples thereof include extracts and plant extracts containing flavone derivatives such as ginkgo biloba.
【０００６】本発明に用いる精油とは、ユーカリ油、チ
ョウジ油、ケイヒ油、カシア皮油、カシア葉油、ハッカ
油、ペパーミント油、芳樟油、カヤプテン油、ニオウリ
油、月桂樹から得られる精油、ベイから得られる精油、
メボウキから得られる精油、リュウノウ樹・リュウノウ
ギクから得られる精油、針葉油、ミル油など通常医薬品
として用いられるものまたは医薬品や食品に添加剤とし
て用いられるものが挙げられ、これらは単独あるいは２
種以上を組み合わせて用いることができる。本発明に用
いる精油成分とは、シネオール、オイゲノール、メチル
オイゲノール、カンフル、ボルネオール、ケイヒアルデ
ヒド、メントールなどが挙げられ、これらは単独あるい
は２種以上を組み合わせて用いることができ、組成物の
0.001〜５％の割合で配合することが好ましい。また、
本発明の精油成分は、前記精油に含まれる主成分として
知られているが、これらは天然物から抽出、精製したも
のでも、あるいは化学的に合成したものでもよく、光学
異性体や立体異性体が存在する場合でも全て使用するこ
とができる。本発明において、精油と精油成分は互いに
組み合わせて用いることも可能である。The essential oils used in the present invention include eucalyptus oil, clove oil, cinnamon oil, cassia peel oil, cassia leaf oil, peppermint oil, peppermint oil, perilla oil, kayapten oil, smelt oil, and essential oil obtained from laurel, Essential oil obtained from the bay,
Examples include essential oils obtained from Mebuki, essential oils obtained from cypress and ryugi, needle leaf oil, mill oil, and the like used as ordinary medicines or those used as additives in medicines and foods. These may be used alone or in combination with 2
A combination of two or more species can be used. Examples of the essential oil component used in the present invention include cineol, eugenol, methyleugenol, camphor, borneol, cinnaldehyde, menthol, and the like. These can be used alone or in combination of two or more,
It is preferable to add it in a proportion of 0.001 to 5%. Also,
The essential oil component of the present invention is known as the main component contained in the essential oil, but these may be extracted from natural products, purified, or chemically synthesized, and may be optical isomers or stereoisomers. Can be used even if In the present invention, the essential oil and the essential oil component can be used in combination with each other.
【０００７】本発明の苦味低減組成物は、医薬品または
食品を製造する一般的な方法で製することができる。例
えば液状の医薬品または食品では苦味を有する成分を
水、エタノールなどの通常用いられる溶剤に溶解または
懸濁し、精油または精油成分をそのまま又は必要に応じ
て、例えばショ糖脂肪酸エステル、ポリオキシエチレン
硬化ヒマシ油60などの界面活性剤、水、エタノール、プ
ロピレングリコール、グリセリンなどの溶剤等に溶解も
しくは懸濁したものを配合し、均一に混和し、必要に応
じて酸類または塩基類などを加えてpHを調節することに
よって製することができる。また、固形の医薬品または
食品では、苦味を有する成分および精油または精油成分
をそのまま又は必要に応じて、例えばデキストリンや無
水ケイ酸などの各種添加剤などと均一に混和し、常法に
準じて散剤、顆粒剤、細粒剤などとすることができる。The bitterness-reducing composition of the present invention can be produced by a general method for producing a medicine or food. For example, in a liquid medicine or food, a component having a bitterness is dissolved or suspended in a commonly used solvent such as water or ethanol, and an essential oil or an essential oil component is used as it is or when necessary, for example, sucrose fatty acid ester, polyoxyethylene hydrogenated castor. Blend a solution such as oil 60 dissolved in or suspended in a solvent such as water, ethanol, propylene glycol, glycerin, etc., mix evenly, and add acids or bases as necessary to adjust the pH. It can be manufactured by adjusting. In the case of solid pharmaceuticals or foods, components having bitterness and essential oils or essential oil components are used as they are or, if necessary, uniformly mixed with various additives such as dextrin and silicic acid anhydride, and powdered according to a conventional method. , Granules, fine granules and the like.
【０００８】さらに、本発明の苦味低減組成物は、必要
に応じて、例えばリン酸リボフラビンナトリウム、塩酸
ピリドキシンなどのビタミン類、塩酸トリプロリジン、
マレイン酸クロルフェニラミン、塩化リゾチーム、カン
ゾウエキスなどの生理活性成分や、例えば安息香酸塩、
パラオキシ安息香酸アルキルエステル類などの防腐剤、
白糖、果糖、ブドウ糖、液糖などの甘味剤、クエン酸、
リンゴ酸などの酸味剤を始めとする矯味剤、乳糖、デン
プン、結晶セルロースなどの賦形剤、ヒドロキシプロピ
ルセルロース、ポリビニルピロリドンなどの結合剤など
の添加剤を加えることができる。The bitterness-reducing composition of the present invention may further contain, for example, vitamins such as riboflavin sodium phosphate and pyridoxine hydrochloride, triprolidine hydrochloride, and the like.
Chlorpheniramine maleate, lysozyme chloride, physiologically active ingredients such as licorice extract, for example, benzoate,
Preservatives such as paraoxybenzoic acid alkyl esters,
Sweeteners such as white sugar, fructose, glucose, liquid sugar, citric acid,
It is possible to add flavoring agents such as malic acid and other flavoring agents, excipients such as lactose, starch and crystalline cellulose, and additives such as binders such as hydroxypropyl cellulose and polyvinylpyrrolidone.
【０００９】このようにして得られた本発明の苦味低減
組成物は、固形および液状の医薬品または食品として用
いることができ、後述のように各成分が有する強い苦味
は従来の方法に比して著しく低減されて服用あるいは摂
取しやすく、極めて有用である。The bitterness-reducing composition of the present invention thus obtained can be used as a solid or liquid drug or food, and as described below, the strong bitterness of each component is higher than that of conventional methods. It is extremely useful because it is significantly reduced and easy to take or ingest.
【００１０】[0010]
【実施例】本発明を詳細に説明するために以下に実施例
及び比較例を挙げるが、本発明はこれによって限定され
るものではない。EXAMPLES Examples and comparative examples will be given below for illustrating the present invention in detail, but the present invention is not limited thereto.
【００１１】実施例１ 銀杏葉抽出エキス１ｇ（銀杏葉10ｇに相当）を精製水に
溶解し、これにユーカリ油20mgを溶解したエタノール
0.5mlを加え、白糖15ｇ、クエン酸 200mg、安息香酸ナ
トリウム50mgを溶解した。この水溶液を精製水で全量 1
00mlとし、ろ紙ろ過後、瞬間滅菌してガラス瓶に 100ml
充填し、キャップを締め清涼飲料とした。EXAMPLE 1 1 g of ginkgo biloba extract (corresponding to 10 g of ginkgo biloba) was dissolved in purified water, and 20 mg of eucalyptus oil was dissolved in this ethanol.
0.5 ml was added to dissolve 15 g of sucrose, 200 mg of citric acid, and 50 mg of sodium benzoate. 1 volume of this aqueous solution with purified water
Make up to 00 ml, filter filter paper, sterilize instantly, and put 100 ml in a glass bottle.
It was filled and the cap was closed to make a soft drink.
【００１２】実施例２ カフェイン 200mgを精製水に溶解し、リン酸リボフラビ
ンナトリウム10mg、塩酸ピリドキシン20mg、白糖15ｇ、
クエン酸 200mg、安息香酸ナトリウム50mgを溶解した。
これにプロピレングリコール 0.5mlにケイヒ油10mg、ハ
ッカ油５mg、ショ糖脂肪酸エステル50mgを溶解したもの
を加え、さらに水酸化ナトリウムの適量を加えpH 4.0に
調整した。この水溶液を精製水で全量 100mlとし、ろ紙
ろ過後、ガラス瓶に50ml充填し、キャップを締め加熱滅
菌して内服液剤とした。Example 2 200 mg of caffeine was dissolved in purified water, and sodium riboflavin phosphate 10 mg, pyridoxine hydrochloride 20 mg, sucrose 15 g,
200 mg of citric acid and 50 mg of sodium benzoate were dissolved.
A solution prepared by dissolving 10 mg of cinnamon oil, 5 mg of mint oil, and 50 mg of sucrose fatty acid ester in 0.5 ml of propylene glycol was added thereto, and an appropriate amount of sodium hydroxide was further added to adjust the pH to 4.0. The total volume of this aqueous solution was adjusted to 100 ml with purified water, and after filtering with filter paper, 50 ml was filled in a glass bottle, the cap was closed, and heat sterilization was performed to obtain an internal solution.
【００１３】実施例３ リン酸ジヒドロコデイン30mg、塩酸メチルエフェドリン
75mgをそれぞれ精製水に溶解した。これにメントール10
mgを溶解したエタノール 0.5mlを加え、さらに果糖・ブ
ドウ糖液糖30ｇ、パラオキシ安息香酸エチル５mgを溶解
し、精製水で全量 100mlとし、ろ紙ろ過後、ガラス瓶に
50ml充填しキャップを締め加熱滅菌してシロップ剤とし
た。Example 3 Dihydrocodeine phosphate 30 mg, methylephedrine hydrochloride
75 mg was dissolved in purified water. Menthol 10
0.5 mg of ethanol containing dissolved mg was added, and further 30 g of fructose / glucose liquid sugar and 5 mg of ethyl paraoxybenzoate were dissolved, and the total volume was adjusted to 100 ml with purified water.
It was filled with 50 ml, closed the cap and sterilized by heating to obtain a syrup.
【００１４】実施例４ ポリオキシエチレン硬化ヒマシ油60 50mgを溶解したプ
ロピレングリコール 0.2ｇにシネオール10mg及びケイヒ
アルデヒド10mgを溶解し、これを精製水に溶解した。さ
らにオウレン流エキス２ml（オウレン２ｇに相当）、白
糖10ｇ、クエン酸 100mg、安息香酸ナトリウム50mgを溶
解した。この水溶液を精製水で全量 100mlとし、ろ紙ろ
過後、ガラス瓶に50ml充填し、キャップを締め加熱滅菌
して内服液剤とした。Example 4 10 mg of cineole and 10 mg of cinnamic aldehyde were dissolved in 0.2 g of propylene glycol in which 50 mg of hydrogenated castor oil of polyoxyethylene 60 was dissolved, and this was dissolved in purified water. Further, 2 ml of the Oren flow extract (corresponding to 2 g of the Oren), 10 g of sucrose, 100 mg of citric acid, and 50 mg of sodium benzoate were dissolved. The total volume of this aqueous solution was adjusted to 100 ml with purified water, and after filtering with filter paper, 50 ml was filled in a glass bottle, the cap was closed, and heat sterilization was performed to obtain an internal solution.
【００１５】実施例５ 乳糖50ｇ、デンプン37ｇ、カルメロースカルシウム５
ｇ、ヒドロキシプロピルセルロース３ｇ及びグアイフェ
ネシン５ｇを取り、これにユーカリ油20mgを加えてよく
攪拌した30％のエタノールを含有した精製水20mlを加
え、練合した後、押し出し造粒し、80℃で乾燥後、アル
ミ分包して顆粒剤とした。Example 5 Lactose 50 g, starch 37 g, carmellose calcium 5
g, hydroxypropyl cellulose 3g and guaifenesin 5g, eucalyptus oil 20mg and well stirred 30% ethanol-containing purified water 20ml, kneaded, extruded and granulated, dried at 80 ℃ Then, it was packaged in aluminum to give granules.
【００１６】実施例６ 乳糖50ｇ、デンプン37ｇ及びポリビニルピロリドンＫ25
３ｇを取り、これにオウレンエキス２ｇ（原生薬量10
ｇ分）及びメントール10mgを加えた30％のエタノールを
含有した精製水20mlを加え、攪拌造粒し、80℃で乾燥
後、アルミ分包して細粒剤とした。Example 6 50 g of lactose, 37 g of starch and polyvinylpyrrolidone K25
Take 3g, and add 2g of the Oren extract (10
g)) and 20 ml of purified water containing 30% ethanol containing 10 mg of menthol were added, and the mixture was granulated with stirring, dried at 80 ° C., and packaged in aluminum to give a fine granule.
【００１７】実施例７ 乳糖50ｇ、デンプン40ｇ、無水ケイ酸５ｇ、リン酸ジヒ
ドロコデイン30mg及び塩酸メチルエフェドリン75mgを混
和し、さらにケイヒ油10mg及びハッカ油５mgを加えてよ
く攪拌、乾燥し、アルミ分包して散剤とした。Example 7 Lactose (50 g), starch (40 g), silicic acid (5 g), dihydrocodeine phosphate (30 mg) and methylephedrine hydrochloride (75 mg) were admixed, and cinnamon oil (10 mg) and peppermint oil (5 mg) were added, and the mixture was well stirred, dried, and packaged in aluminum. It was made into a powder.
【００１８】比較例１ 銀杏葉抽出エキス１ｇ（銀杏葉10ｇに相当）を精製水に
溶解し、これに白糖15ｇ、クエン酸 200mg、安息香酸
ナトリウム50mgを溶解した。この水溶液を精製水で全量
100mlとし、実施例１と同様に操作して清涼飲料とし
た。Comparative Example 1 1 g of ginkgo biloba extract (corresponding to 10 g of ginkgo biloba) was dissolved in purified water, and 15 g of sucrose, 200 mg of citric acid, and 50 mg of sodium benzoate were dissolved in this. The total amount of this aqueous solution is purified water
The amount was 100 ml and the same operation as in Example 1 was carried out to obtain a soft drink.
【００１９】比較例２ カフェイン 200mgを精製水に溶解し、リン酸リボフラビ
ンナトリウム10mg、塩酸ピリドキシン20mg、白糖15ｇ、
クエン酸 200mg、安息香酸ナトリウム50mgを溶解した。
これに水酸化ナトリウムの適量を加えpH 4.0に調整し
た。この水溶液を精製水で全量 100mlとし、実施例２と
同様に操作して内服液剤とした。Comparative Example 2 200 mg of caffeine was dissolved in purified water, and 10 mg of sodium riboflavin phosphate, 20 mg of pyridoxine hydrochloride, 15 g of sucrose,
200 mg of citric acid and 50 mg of sodium benzoate were dissolved.
The pH was adjusted to 4.0 by adding an appropriate amount of sodium hydroxide. The total amount of this aqueous solution was 100 ml with purified water, and the same procedure as in Example 2 was carried out to give an internal solution.
【００２０】比較例３ リン酸ジヒドロコデイン30mg、塩酸メチルエフェドリン
75mgをそれそれ精製水に溶解した。これに果糖・ブドウ
糖液糖30ｇ、パラオキシ安息香酸エチル５mgを溶解し、
精製水で全量 100mlとし、実施例３と同様に操作してシ
ロップ剤とした。Comparative Example 3 Dihydrocodeine phosphate 30 mg, methylephedrine hydrochloride
75 mg each was dissolved in purified water. 30 g of fructose / glucose liquid sugar and 5 mg of ethyl paraoxybenzoate were dissolved in this,
The total amount was 100 ml with purified water, and the same procedure as in Example 3 was carried out to obtain a syrup.
【００２１】比較例４ オウレン流エキス２ml（オウレン２ｇに相当）を精製水
に溶解し、これに白糖10ｇ、クエン酸 100mg、安息香酸
ナトリウム50mgを溶解した。この水溶液を精製水で全量
100mlとし、実施例４と同様に操作して内服液剤とし
た。Comparative Example 4 2 ml of the Oren flow extract (corresponding to 2 g of the Oren) was dissolved in purified water, and 10 g of sucrose, 100 mg of citric acid and 50 mg of sodium benzoate were dissolved in this. The total amount of this aqueous solution is purified water
The amount was 100 ml, and the same operation as in Example 4 was carried out to give an internal solution.
【００２２】比較例５ 乳糖50ｇ、デンプン37ｇ、カルメロースカルシウム５
ｇ、ヒドロキシプロピルセルロース３ｇ及びグアイフェ
ネシン５ｇを取り、これに30％のエタノールを含有した
精製水20mlを加え、練合した後、押し出し造粒し、実施
例５と同様に操作して顆粒剤とした。Comparative Example 5 Lactose 50 g, starch 37 g, carmellose calcium 5
g, hydroxypropyl cellulose 3 g and guaifenesin 5 g were added thereto, 20 ml of purified water containing 30% ethanol was added, kneaded, extruded and granulated, and operated in the same manner as in Example 5 to obtain granules. .
【００２３】比較例６ 乳糖50ｇ、デンプン37ｇ及びポリビニルピロリドンＫ25
３ｇを取り、これにオウレンエキス２ｇ（原生薬量10
ｇ分）を加えた30％のエタノールを含有した精製水20ml
を加え、攪拌造粒した後、実施例６と同様に操作して細
粒剤とした。Comparative Example 6 50 g of lactose, 37 g of starch and polyvinylpyrrolidone K25
Take 3g, and add 2g of the Oren extract (10
20 ml of purified water containing 30% ethanol added with
After adding and stirring and granulating, the same procedure as in Example 6 was carried out to obtain a fine granule.
【００２４】比較例７ 乳糖50ｇ、デンプン40ｇ、無水ケイ酸５ｇ、リン酸ジヒ
ドロコデイン30mg及び塩酸メチルエフェドリン75mgを混
和した後、実施例７と同様に操作して散剤とした。Comparative Example 7 Lactose (50 g), starch (40 g), silicic acid (5 g), dihydrocodeine phosphate (30 mg) and methylephedrine hydrochloride (75 mg) were mixed, and the same procedure as in Example 7 was repeated to give a powder.
【００２５】苦味に関する官能検査 予め苦みの識別に関して比較的感受性が高いことを確認
した健康な成人30名を選択し、苦みに関する官能検査を
行った。官能検査は、各検体の苦みを「非常に苦い」、
「苦い」、「僅かに苦い」、「苦くない」の４段階で評
価した。各被験者が試験する検体の順序は、全てランダ
マイズした。結果を各検体に付けられた評価の度数を割
合として表１に示す。Sensory test for bitterness 30 healthy adults who had been confirmed to have relatively high sensitivity for identifying bitterness were selected and subjected to a sensory test for bitterness. The sensory test shows the bitterness of each sample as "very bitter",
The evaluation was made in 4 grades of "bitter", "slightly bitter" and "not bitter". The order of specimens tested by each subject was randomized. The results are shown in Table 1 as the ratio of the evaluation frequency assigned to each sample.
【００２６】[0026]
【表１】 [Table 1]
【００２７】表１から明らかなように、比較例ではいず
れも「非常に苦い」、「苦い」と評価された割合が多い
のに対して、本発明の実施例では「非常に苦い」、「苦
い」という評価が極めて少なかった。As is clear from Table 1, in the comparative examples, the percentages evaluated as "very bitter" and "bitter" are large, whereas in the examples of the present invention, "very bitter" and "bitter". There were very few evaluations of "bitterness".
【００２８】[0028]
【発明の効果】本発明の苦味低減組成物は、苦味を有す
る成分に精油または精油成分を配合することにより、そ
の苦味を低減して、医薬品または食品として経口的に服
用あるいは摂取しやすくし、固形物のみならず液状のも
のにも適用でき極めて有用である。The bitterness-reducing composition of the present invention reduces the bitterness by blending an essential oil or an essential oil component with an ingredient having a bitterness, thereby facilitating oral administration or ingestion as a pharmaceutical or food, It is extremely useful as it can be applied to liquid as well as solid substances.
Claims (2)
徴とする苦味低減組成物。1. A bitterness-reducing composition comprising blending an essential oil to reduce bitterness.
を特徴とする苦味低減組成物。2. A bitterness-reducing composition characterized by containing an essential oil component to reduce bitterness.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4081419A JPH05255126A (en) | 1992-03-04 | 1992-03-04 | Bitter taste-reducing composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4081419A JPH05255126A (en) | 1992-03-04 | 1992-03-04 | Bitter taste-reducing composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH05255126A true JPH05255126A (en) | 1993-10-05 |
Family
ID=13745837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4081419A Pending JPH05255126A (en) | 1992-03-04 | 1992-03-04 | Bitter taste-reducing composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH05255126A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1036292A (en) * | 1996-07-24 | 1998-02-10 | Taisho Pharmaceut Co Ltd | Liquid agent reduced in bitter taste |
| WO2001087095A1 (en) * | 2000-05-15 | 2001-11-22 | Unilever Plc | Ambient stable beverage |
| JP2003095945A (en) * | 2001-09-27 | 2003-04-03 | Zeria Pharmaceut Co Ltd | Liquid medicine including nizatidine with masked bitterness thereof |
| WO2005025622A1 (en) * | 2003-09-12 | 2005-03-24 | Ryukakusan Co. Ltd. | Bitterness-masking particulate jelly beverage |
| JPWO2003097027A1 (en) * | 2002-05-22 | 2005-10-06 | 日本製薬株式会社 | L-menthol oil-in-water emulsion |
| JP2011148776A (en) * | 2009-12-22 | 2011-08-04 | Taisho Pharmaceutical Co Ltd | Liquid preparation composition |
| JP5220942B1 (en) * | 2012-08-07 | 2013-06-26 | 長谷川香料株式会社 | Menthol bitterness inhibitor |
| JP2016027829A (en) * | 2012-03-23 | 2016-02-25 | 大正製薬株式会社 | Carbonated beverage |
-
1992
- 1992-03-04 JP JP4081419A patent/JPH05255126A/en active Pending
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1036292A (en) * | 1996-07-24 | 1998-02-10 | Taisho Pharmaceut Co Ltd | Liquid agent reduced in bitter taste |
| WO2001087095A1 (en) * | 2000-05-15 | 2001-11-22 | Unilever Plc | Ambient stable beverage |
| US6761919B2 (en) | 2000-05-15 | 2004-07-13 | Lipton, Division Of Conopco, Inc. | Ambient stable beverage |
| JP2003095945A (en) * | 2001-09-27 | 2003-04-03 | Zeria Pharmaceut Co Ltd | Liquid medicine including nizatidine with masked bitterness thereof |
| JPWO2003097027A1 (en) * | 2002-05-22 | 2005-10-06 | 日本製薬株式会社 | L-menthol oil-in-water emulsion |
| JPWO2005025622A1 (en) * | 2003-09-12 | 2006-11-16 | 株式会社龍角散 | Bitter masking granular jelly beverage |
| WO2005025622A1 (en) * | 2003-09-12 | 2005-03-24 | Ryukakusan Co. Ltd. | Bitterness-masking particulate jelly beverage |
| AU2004271853B2 (en) * | 2003-09-12 | 2009-03-12 | Ryukakusan Co. Ltd. | Granular jelly drink capable of masking bitter |
| JP4647493B2 (en) * | 2003-09-12 | 2011-03-09 | 株式会社龍角散 | Bitter masking granular jelly beverage |
| KR101059057B1 (en) * | 2003-09-12 | 2011-08-24 | 류가쿠산 가부시키가이샤 | Granular Jelly Drink Can Block Bitter Taste |
| US8287897B2 (en) | 2003-09-12 | 2012-10-16 | Ryukakusan Co., Ltd. | Bitterness-masking particulate jelly beverage |
| JP2011148776A (en) * | 2009-12-22 | 2011-08-04 | Taisho Pharmaceutical Co Ltd | Liquid preparation composition |
| JP2016027829A (en) * | 2012-03-23 | 2016-02-25 | 大正製薬株式会社 | Carbonated beverage |
| JP5220942B1 (en) * | 2012-08-07 | 2013-06-26 | 長谷川香料株式会社 | Menthol bitterness inhibitor |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU635283B2 (en) | Aqeous pharmaceutical suspension for substantially water insoluble pharmaceutical actives | |
| KR100533346B1 (en) | Chewable soft capsules having improved administration properties and process for producing the same | |
| DE60132851T2 (en) | Medicines for the prevention, alleviation or treatment of hypertension | |
| JP2818220B2 (en) | Composition containing water-containing organic solvent extract for food, composition containing water-containing organic solvent extract for medicine, and methods for producing them | |
| KR20100051850A (en) | Medical composition containing rebamipide | |
| EP0265226A2 (en) | Spray dried acetaminophen | |
| JP3859988B2 (en) | Antihypertensive agent | |
| JPH08225453A (en) | Lipoprotein (a) depressor, cholesterol depressor and medicine containing the same | |
| JPH05255126A (en) | Bitter taste-reducing composition | |
| JPH0465051B2 (en) | ||
| US20200188468A1 (en) | A coated costus composition enriched with triterpenoids and a method of preparation of the same | |
| RU2474432C2 (en) | METHOD FOR PREPARING Pelargonium sidoides AND Pelargonium reniforme EXTRACT | |
| KR100678837B1 (en) | Syrup composition comprising dexibupropen as an active ingredient and method for the preparation thereof | |
| JPH05502457A (en) | Kava kava extracts, their manufacturing process and uses | |
| JP3130327B2 (en) | Liver dysfunction preventive agent and functional food having hepatic dysfunction preventive action | |
| JP2001122777A (en) | Antiulcer agent | |
| JP2004522698A (en) | Perfume systems for pharmaceutical compositions and methods for producing such compositions | |
| RU2752781C1 (en) | Encapsulated form food baa | |
| US20040146468A1 (en) | Oral compositon comprising an extract from the bark of albizzia myrioplylla | |
| RU2756855C1 (en) | Biologically active food supplement of encapsulated form | |
| RU2759731C1 (en) | Biologically active dietary supplement in encapsulated form | |
| KR101458670B1 (en) | Pharmaceutical composition comprising branched chain amino acids as active ingredients and the preparation method thereof | |
| JP2005170804A (en) | Antiallergic agent | |
| US20050271756A1 (en) | Plant extraction method and extract | |
| KR20020004190A (en) | Composition for instant ginseng tea |